Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early stage and de novo antibody-drug conjugates (ADCs) and multispecific antibodies for oncology. Read More
Industry watchers will be tracking closely Replimune Group Inc.’s latest attempt to secure U.S. FDA approval of its advanced melanoma candidate, RP-1 (vusolimogene oderparepvec). The company announced Friday it had reached alignment for resubmitting the twice-rejected BLA with the agency, which it said has pledged to prioritize the review. Read More
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma was successful. Nearly three months later, the magnitude of success for its Pomalyst (pomalidomide) successor is clear. Read More
“I need to be honest with you about something important. Most previous Ebola outbreaks in the Democratic Republic of Congo (DRC) were caused by a virus called Ebola Zaire, for which we have vaccines and treatments. This outbreak is caused by a different virus called Ebola Bundibugyo. There are currently no approved vaccines or treatments for it.” This was the stark message from Tedros Adhanom Ghebreyesus, director general of the World Health Organization (WHO) in an open letter to the people of the DRC, as he traveled to the country on Friday, May 29. Read More
China’s National Medical Products Administration has issued final implementation measures for drug trial data protection that mark a significant step toward aligning China’s pharmaceutical intellectual property framework with global standards. Read More
BioWorld tracked 143 clinical trial readouts across phases I through III in April 2026, down from 209 in March, but roughly in line with 152 in February and 144 in January. By phase, April’s readouts included 47 from phase I, 59 from phase II and 37 in phase III. Among phase III programs, 15 trials reported positive results and two failed to meet primary endpoints. Read More
The human pancreas often contains lesions that are common in the population and that, although they can become malignant, usually do not. To understand when this occurs and how these pancreatic cancer precursor lesions, known as pancreatic intraepithelial neoplasias (PanIN), evolve, scientists at the University of Michigan analyzed their gene expression patterns and their cellular microenvironment. Read More
New hires and promotions in the biopharma and med-tech industries, including: Alto Neuroscience, Aptevo, Brainstorm Cell, Briya, Compass Pathways, Countable Labs, Enplusone, Pharmaessentia, Topadur, Treos, Zentalis. Read More
Biopharma and med-tech companies raising money in public or private financings, including: Countable Labs, Maculaser, Medicenna, Medicus, Polaryx, Psilera, Secretome, Veraxa. Read More
Clinical updates for biopharma and med tech, including data readouts and publications: Anaveon, Beone, Biovica, Bioxcel, Bold Therapeutics, GSK, Ionis, Menarini, Molecular Targeting, Nrx, Ono Pharma, Pepromene, Repairon, Rubedo, Viromissile. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Brainstorm, Cambridge Cognition, Cliniquantum, Dyadic, Eli Lilly, Foxo, Ipsen, LongevityFP, Lunai, Neurothera, OSR, Pasylanta, Scisparc, Vaximm, XL-protein. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Abbvie, Beren, Cogent, Corcept, Enterome, Gene Solutions, Innocare, Ironwood, Renovorx, Sanofi, Solu, Zenas. Read More
